3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid
C23H29FN4O3 — CID 90310757
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid
3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid (PubChem CID 90310757) has the molecular formula C23H29FN4O3 and a molecular weight of 428.51 g/mol. Its IUPAC name is 3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid.
Molecular Properties
| Compound Name | 3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid |
|---|---|
| PubChem CID | 90310757 |
| Molecular Formula | C23H29FN4O3 |
| Molecular Weight | 428.51 g/mol |
| Exact Mass | 428.22 |
| IUPAC Name | 3-[[3-(5-aminopyrazin-2-yl)-6-cyclobutyl-2-fluorophenoxy]methyl]-2-tert-butylazetidine-1-carboxylic acid |
| SMILES | CC(C)(C)C1C(COc2c(C3CCC3)ccc(-c3cnc(N)cn3)c2F)CN1C(=O)O |
| InChI | InChI=1S/C23H29FN4O3/c1-23(2,3)21-14(11-28(21)22(29)30)12-31-20-15(13-5-4-6-13)7-8-16(19(20)24)17-9-27-18(25)10-26-17/h7-10,13-14,21H,4-6,11-12H2,1-3H3,(H2,25,27)(H,29,30) |
| InChIKey | ZGDQCAWRELXKQU-UHFFFAOYSA-N |
| XLogP | 4.54 |
| TPSA | 101.57 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 428.51 |
| LogP ≤ 5 | 4.54 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 90310757 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.